Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Colorectal Neoplasms 13Triple Negative Breast Neoplasms 3Colonic Neoplasms 3Carcinoma, Non-Small-Cell Lung 3NSCLC 2Endometrial Neoplasms 2Breast Neoplasms 2Advanced Solid Tumors 2Squamous Cell Carcinoma of Head and Neck 1Rectal Neoplasms 1Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma 1Lung Neoplasms 1Hodgkin Disease 1HER2-positive Colorectal Cancer 1HER2 IHC3+ Advanced Colorectal Cancer 1Esophageal Neoplasms 1Colorectal Cancer Metastatic 1Burkitt Lymphoma 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1Advanced Colorectal Cancer 1

Interventions

Carboplatin 7aflutinib 5Pemetrexed 5osimertinib 4Gefitinib 4HM781-36B 3rezivertinib 2pembrolizumab 2Paclitaxel 2HMPL-013 2Docetaxel 2Cisplatin 2Albumin-Bound Paclitaxel 2tipifarnib 1sulindac sulfone 1spartalizumab 1icotinib 1aumolertinib 1apatinib 1Vinorelbine 1Taxes 1Gemcitabine 1Erlotinib Hydrochloride 1Clinical Trials, Phase I as Topic 1Cetuximab 1CP protocol 1Bortezomib 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × NSCLC × HMPL-013 × Clear all
NCT02976116 2019-11-15

A Phase II Study of Fruquintinib in Combination With Gefitinib in Patients With Advanced Non-small Cell Lung Cancer

Hutchmed

Phase 2 Completed
50 enrolled
Thoracic

NSCLC

NCT02691299 2019-02-12

FALUCA

Hutchmed

Phase 3 Completed
527 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡